Core Insights - BioCryst Pharmaceuticals has secured reimbursement approval for ORLADEYO (berotralstat) in the Netherlands, enabling routine prevention of hereditary angioedema (HAE) attacks for patients aged 12 and older [1][2] - This approval signifies national reimbursement for ORLADEYO across all major European countries, enhancing access to the first oral, once-daily preventive therapy for HAE patients [1][3] Company Overview - BioCryst Pharmaceuticals is a global biotechnology company focused on improving the lives of individuals with hereditary angioedema and other rare diseases, utilizing expertise in structure-guided drug design [11] - The company has commercialized ORLADEYO, the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of small-molecule and protein therapies [11] Product Information - ORLADEYO is indicated for the prophylaxis of hereditary angioedema attacks in adults and pediatric patients aged 12 years and older, with one capsule taken daily to reduce plasma kallikrein activity [4][5] - The safety and effectiveness of ORLADEYO for treating acute HAE attacks have not been established, and it is not recommended for such use [6][10]